関連する実験動画
Updated: Feb 26, 2026

09:43
Isolation and Characterization of RNA-Containing Exosomes
Published on: January 9, 2012
100.6K
エクソソームRNA非遮蔽カップル 腫瘍におけるパターン認識受容体シグナルへのストロマル活性化
Barzin Y Nabet1, Yu Qiu1, Jacob E Shabason1
1Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Cell
|July 15, 2017
まとめ
乳がん細胞はストロマ NOTCH-MYCを誘発し,RNA RN7SL1を増加させる. エキソソムの非遮蔽RN7SL1は,パターン認識受容体 (PRRs) を活性化することによって,炎症,腫瘍の成長,転移,および治療抵抗を促進する.
科学分野:
- 分子生物学
- 癌の研究
- 免疫学
背景:
- ストロマル・フィブロブラストとがん細胞は相互作用し,がんの進行と治療抵抗性に影響を与えます.
- 内生RNAはダメージに関連した分子パターン (DAMP) としてパターン認識受容体 (PRR) を活性化しますが,通常は遮断されます.
- ストロマ細胞から放出される非シールドRNAは炎症とがんの攻撃性を促進する.
研究 の 目的:
- 癌の進行と治療抵抗におけるストロマルRNA調節の役割を調査する.
- 特定のRNA分子を特定し,がん細胞との交流に関与する経路を特定する.
- 炎症や腫瘍を誘発するシグナルを放出させる仕組みを理解する.
主な方法:
- 乳がん細胞によって誘発されたストロマ線維細胞におけるNOTCH-MYCシグナリングを調査した.
- RNA RN7SL1の発現を調節するPOL3の役割を分析した.
- RN7SL1とRNA結合タンパク質SRP9/ 14の相互作用を調べました.
- 免疫細胞と癌細胞へのエクソソームによる非遮蔽RN7SL1の転送を研究した.
- RIG-Iのようなパターン認識受容体 (PRR) の活性化を評価した.
- 患者の腫瘍と血液サンプルを使って 確認した結果です
主要な成果:
- 乳がん細胞はストロマ NOTCH-MYCを誘発し,RN7SL1の発現を増加させます.
- 増加したRN7SL1は,SRP9 / 14との結合を変化させ,シールドされていないRN7SL1を生成します.
- 保護されていないRN7SL1は,ストロマの外体内に放出され,他の細胞に移送されます.
- 免疫細胞では,保護されていないRN7SL1が炎症反応を引き起こします.
- 乳がん細胞では,非遮蔽RN7SL1がRIG- Iを活性化し,腫瘍の成長,転移,および治療抵抗性を高めます.
- 患者のサンプルから得られた証拠は,攻撃的な癌の特徴におけるRNAの非遮蔽の役割を裏付けています.
結論:
- RNAの脱シールドの調節は,RNA DAMPの放出とストロマの活性化を結びつける重要なメカニズムです.
- 保護されていないRN7SL1は,成長,転移,および治療抵抗性を含む攻撃的な癌のフェノタイプを促進します.
- 乳がんの新たな治療戦略を 提供できるかもしれません
関連する概念動画
Overview of Exosomes
3.8K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.8K
MicroRNAs
4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs
24.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Cancer Stem Cells and Tumor Maintenance
6.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K

